The Obstructive Lung Disease Market focuses on ailments such asthma or chronic obstructive pulmonary disease (COPD) where competing strategies employed by pharmaceutical companies have resulted in dynamic market share positioning techniques being adopted by major players. One key strategy involves continuous innovation in treatment options available. This means that due to the varying types of obstructive lung diseases existing today, various organizations make significant investments into researches to bring up new forms of therapies.
Pricing strategies emerge as a critical factor in market share positioning within the Obstructive Lung Disease Market. Various firms in this industry go for diverse pricing strategies based on the level of effectiveness of their treatment, ability of patients to purchase them as well as reimbursement considerations . While some adopt premium prices in order to promote the superiority of their treatments, others have made their prices affordable to reach a larger population of patients. For companies that want to capture much market share and cater for customers of different economic statuses buying obstructive lung treatment is all about striking a balance between affordability and perceived worthiness.
Efficient marketing and distribution channels are key in enhancing a company’s market share within the Obstructive Lung Disease Market. Major pharmaceutical players spend heavily on creating awareness about its solutions among health providers and end users. On the other hand targeted promotional activities help create strong brand presence which endows some trustworthiness into these services at the same time optimizing distribution networks ensures wide spread availability thereby taking care of diverse geographic areas that have got large populations. This also expands visibility through strategic placement while contributing towards attainments of more market shares.
Customization and patient-centric approaches are gaining prominence as key strategies in the Obstructive Lung Disease Market. With regard to this, they have introduced personalized medicine with genetic testing being used for targeted therapies. By so doing, such customization does not only make treatments effective but also it enhances competitive advantage by showing commitment to be patient focused thus giving an organization position support.
The obstructive lung disease market is expected to reach USD 51.3 Billion at a CAGR of 4.7% during the forecast period 2024-2030. Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.
As per the Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as an occupational hazard in people working in agriculture, mining, plastics, and other industries.
Governments across each country have implemented regulations for the production, standardization, and utilization of COPD devices. These devices are divided into categories –Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.
However, stringent government regulatory requirement for the approval of asthma and COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs restrict the market growth.
Intended Audience
The obstructive lung disease market is segmented on the basis of disease type, product type, drug class, route of administration and end-users.
On the basis of disease type, the obstructive lung disease market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others.
On the basis of product type obstructive lung disease market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers.
On the basis of drug class, the obstructive lung disease market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.
On the basis of route of administration, obstructive lung disease market is segmented into oral, inhaler, intravenous, subcutaneous, and others.
On the basis of end-user, the obstructive lung disease market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.
Some of key the players in the obstructive lung disease market are
The obstructive lung disease market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is projected to hold the largest share of the obstructive lung disease market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.
The European obstructive lung disease market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.
Countries such as China, Japan, and India in Asia Pacific are also poised to be promising markets for obstructive lung disease in the near future. The healthcare expenditure in Asia increased due to an extension of state healthcare programs and the increasing affluence of the population. India is anticipated to witness an expansion in spending due to a government resolution to enhance healthcare services. Moreover, China and South Korea are s triving to develop their biotechnology sector for diagnosis purpose. China’s efforts to develop its biotech sector has shown good results in sectors such as vaccines and biological products and the same can be expected in the obstructive lung disease industry. However, low research and development (R&D) yields, high infrastructure cost, stringent regulatory framework are some of the restraints of the obstructive lung disease market.
The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.
Recent Development
November 2023: Lupin partners with Mark Cuban's company and COPD Foundation to improve availability and affordability of drugs to treat COPD in the US.
October 2023: AstraZeneca and Boehringer Ingelheim announce new clinical trials for their inhaled triple therapy for COPD.Novartis receives FDA approval for its new oral bronchodilator for COPD.
September 2023: GSK and Theravance Biopharmaceuticals announce new clinical trials for their inhaled dual bronchodilator for COPD.ResMed launches new COPD management platform.
August 2023: Philips Respironics launches new COPD therapy device.GlaxoSmithKline announces new partnership with COPD Foundation to improve care for people with COPD.
July 2023: Pfizer receives FDA approval for its new inhaled triple therapy for COPD.Teva announces new partnership with COPD Foundation to improve access to affordable COPD medications.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)